TG103
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Status n/r · Enrollment 208
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| TG103, 15 mg | n/r | n/r | n/r | n/r |
| TG103, 22.5 mg | n/r | n/r | n/r | n/r |
| TG103, 30 mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- TG103, 15 mg: endpoint not reported
- TG103, 22.5 mg: endpoint not reported
- TG103, 30 mg: endpoint not reported
- Placebo: endpoint not reported